Dysport® (abobotulinumtoxinA) – Expanded indication

- On July 9, 2020, Ipsen Biopharmaceuticals announced the FDA approval of Dysport (abobotulinumtoxinA), for the treatment of spasticity in patients 2 years of age and older.
    - This approval expands and streamlines the previous indication which was for the treatment of spasticity in adults; treatment of upper limb spasticity in pediatric patients 2 years of age and older, excluding spasticity caused by cerebral palsy; and treatment of lower limb spasticity in pediatric patients 2 years of age and older.
- Dysport is also approved for cervical dystonia and glabellar lines
- This label expansion is based on Ipsen Biopharmaceuticals and another manufacturer (Allergan) selectively waiving orphan exclusivity marketing rights each company held for the use of their respective neurotoxins in the treatment of pediatric patients with spasticity caused by cerebral palsy.
- Dysport carries a boxed warning for distant spread of toxin effect.
- The recommended total dose of Dysport for pediatric upper limb spasticity is 8 units/kg to 16 units/kg per limb. The maximum recommended total dose administered per treatment session must not exceed 16 units/kg or 640 units, whichever is lower.
- Refer to the Dysport drug label for additional administration recommendations and for dosing for all of Dysport's other indications.